[68Ga]-pentixafor PET/CT for CXCR4-mediated imaging of vestibular schwannomas

Maria Breun, Camelia M. Monoranu, Almuth F. Kessler, Cordula Matthies, Mario Löhr, Carsten Hagemann, Andreas Schirbel, Steven Rowe, Martin Gilbert Pomper, Andreas K. Buck, Hans Jürgen Wester, Ralf Ingo Ernestus, Constantin Lapa

Research output: Contribution to journalArticle

Abstract

We have recently demonstrated CXCR4 overexpression in vestibular schwannomas (VS). This study investigated the feasibility of CXCR4-directed positron emission tomography/computed tomography (PET/CT) imaging of VS using the radiolabeled chemokine ligand [68Ga]Pentixafor. Methods: 4 patients with 6 primarily diagnosed or pretreated/observed VS were enrolled. All subjects underwent [68Ga]Pentixafor PET/CT prior to surgical resection. Images were analyzed visually and semi-quantitatively for CXCR4 expression including calculation of tumor-to-background ratios (TBR). Immunohistochemistry served as standard of reference in three patients. Results: [68Ga]Pentixafor PET/CT was visually positive in all cases. SUVmean and SUVmax were 3.0 ± 0.3 and 3.8 ± 0.4 and TBRmean and TBRmax were 4.0 ± 1.4 and 5.0 ± 1.7, respectively. Histological analysis confirmed CXCR4 expression in tumors. Conclusion: Non-invasive imaging of CXCR4 expression using [68Ga]Pentixafor PET/CT of VS is feasible and could prove useful for in vivo assessment of CXCR4 expression.

Original languageEnglish (US)
Article number503
JournalFrontiers in Oncology
Volume9
Issue numberJUN
DOIs
StatePublished - Jan 1 2019

Fingerprint

Acoustic Neuroma
Feasibility Studies
Chemokines
Neoplasms
Immunohistochemistry
Ligands
Positron Emission Tomography Computed Tomography
68Ga-pentixafor

Keywords

  • CXCR4
  • Molecular imaging
  • Pentixafor
  • PET/CT
  • Vestibular schwannoma

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Breun, M., Monoranu, C. M., Kessler, A. F., Matthies, C., Löhr, M., Hagemann, C., ... Lapa, C. (2019). [68Ga]-pentixafor PET/CT for CXCR4-mediated imaging of vestibular schwannomas. Frontiers in Oncology, 9(JUN), [503]. https://doi.org/10.3389/fonc.2019.00503

[68Ga]-pentixafor PET/CT for CXCR4-mediated imaging of vestibular schwannomas. / Breun, Maria; Monoranu, Camelia M.; Kessler, Almuth F.; Matthies, Cordula; Löhr, Mario; Hagemann, Carsten; Schirbel, Andreas; Rowe, Steven; Pomper, Martin Gilbert; Buck, Andreas K.; Wester, Hans Jürgen; Ernestus, Ralf Ingo; Lapa, Constantin.

In: Frontiers in Oncology, Vol. 9, No. JUN, 503, 01.01.2019.

Research output: Contribution to journalArticle

Breun, M, Monoranu, CM, Kessler, AF, Matthies, C, Löhr, M, Hagemann, C, Schirbel, A, Rowe, S, Pomper, MG, Buck, AK, Wester, HJ, Ernestus, RI & Lapa, C 2019, '[68Ga]-pentixafor PET/CT for CXCR4-mediated imaging of vestibular schwannomas', Frontiers in Oncology, vol. 9, no. JUN, 503. https://doi.org/10.3389/fonc.2019.00503
Breun M, Monoranu CM, Kessler AF, Matthies C, Löhr M, Hagemann C et al. [68Ga]-pentixafor PET/CT for CXCR4-mediated imaging of vestibular schwannomas. Frontiers in Oncology. 2019 Jan 1;9(JUN). 503. https://doi.org/10.3389/fonc.2019.00503
Breun, Maria ; Monoranu, Camelia M. ; Kessler, Almuth F. ; Matthies, Cordula ; Löhr, Mario ; Hagemann, Carsten ; Schirbel, Andreas ; Rowe, Steven ; Pomper, Martin Gilbert ; Buck, Andreas K. ; Wester, Hans Jürgen ; Ernestus, Ralf Ingo ; Lapa, Constantin. / [68Ga]-pentixafor PET/CT for CXCR4-mediated imaging of vestibular schwannomas. In: Frontiers in Oncology. 2019 ; Vol. 9, No. JUN.
@article{44972cdb2fb54b2397d83047fb2c0149,
title = "[68Ga]-pentixafor PET/CT for CXCR4-mediated imaging of vestibular schwannomas",
abstract = "We have recently demonstrated CXCR4 overexpression in vestibular schwannomas (VS). This study investigated the feasibility of CXCR4-directed positron emission tomography/computed tomography (PET/CT) imaging of VS using the radiolabeled chemokine ligand [68Ga]Pentixafor. Methods: 4 patients with 6 primarily diagnosed or pretreated/observed VS were enrolled. All subjects underwent [68Ga]Pentixafor PET/CT prior to surgical resection. Images were analyzed visually and semi-quantitatively for CXCR4 expression including calculation of tumor-to-background ratios (TBR). Immunohistochemistry served as standard of reference in three patients. Results: [68Ga]Pentixafor PET/CT was visually positive in all cases. SUVmean and SUVmax were 3.0 ± 0.3 and 3.8 ± 0.4 and TBRmean and TBRmax were 4.0 ± 1.4 and 5.0 ± 1.7, respectively. Histological analysis confirmed CXCR4 expression in tumors. Conclusion: Non-invasive imaging of CXCR4 expression using [68Ga]Pentixafor PET/CT of VS is feasible and could prove useful for in vivo assessment of CXCR4 expression.",
keywords = "CXCR4, Molecular imaging, Pentixafor, PET/CT, Vestibular schwannoma",
author = "Maria Breun and Monoranu, {Camelia M.} and Kessler, {Almuth F.} and Cordula Matthies and Mario L{\"o}hr and Carsten Hagemann and Andreas Schirbel and Steven Rowe and Pomper, {Martin Gilbert} and Buck, {Andreas K.} and Wester, {Hans J{\"u}rgen} and Ernestus, {Ralf Ingo} and Constantin Lapa",
year = "2019",
month = "1",
day = "1",
doi = "10.3389/fonc.2019.00503",
language = "English (US)",
volume = "9",
journal = "Frontiers in Oncology",
issn = "2234-943X",
publisher = "Frontiers Media S. A.",
number = "JUN",

}

TY - JOUR

T1 - [68Ga]-pentixafor PET/CT for CXCR4-mediated imaging of vestibular schwannomas

AU - Breun, Maria

AU - Monoranu, Camelia M.

AU - Kessler, Almuth F.

AU - Matthies, Cordula

AU - Löhr, Mario

AU - Hagemann, Carsten

AU - Schirbel, Andreas

AU - Rowe, Steven

AU - Pomper, Martin Gilbert

AU - Buck, Andreas K.

AU - Wester, Hans Jürgen

AU - Ernestus, Ralf Ingo

AU - Lapa, Constantin

PY - 2019/1/1

Y1 - 2019/1/1

N2 - We have recently demonstrated CXCR4 overexpression in vestibular schwannomas (VS). This study investigated the feasibility of CXCR4-directed positron emission tomography/computed tomography (PET/CT) imaging of VS using the radiolabeled chemokine ligand [68Ga]Pentixafor. Methods: 4 patients with 6 primarily diagnosed or pretreated/observed VS were enrolled. All subjects underwent [68Ga]Pentixafor PET/CT prior to surgical resection. Images were analyzed visually and semi-quantitatively for CXCR4 expression including calculation of tumor-to-background ratios (TBR). Immunohistochemistry served as standard of reference in three patients. Results: [68Ga]Pentixafor PET/CT was visually positive in all cases. SUVmean and SUVmax were 3.0 ± 0.3 and 3.8 ± 0.4 and TBRmean and TBRmax were 4.0 ± 1.4 and 5.0 ± 1.7, respectively. Histological analysis confirmed CXCR4 expression in tumors. Conclusion: Non-invasive imaging of CXCR4 expression using [68Ga]Pentixafor PET/CT of VS is feasible and could prove useful for in vivo assessment of CXCR4 expression.

AB - We have recently demonstrated CXCR4 overexpression in vestibular schwannomas (VS). This study investigated the feasibility of CXCR4-directed positron emission tomography/computed tomography (PET/CT) imaging of VS using the radiolabeled chemokine ligand [68Ga]Pentixafor. Methods: 4 patients with 6 primarily diagnosed or pretreated/observed VS were enrolled. All subjects underwent [68Ga]Pentixafor PET/CT prior to surgical resection. Images were analyzed visually and semi-quantitatively for CXCR4 expression including calculation of tumor-to-background ratios (TBR). Immunohistochemistry served as standard of reference in three patients. Results: [68Ga]Pentixafor PET/CT was visually positive in all cases. SUVmean and SUVmax were 3.0 ± 0.3 and 3.8 ± 0.4 and TBRmean and TBRmax were 4.0 ± 1.4 and 5.0 ± 1.7, respectively. Histological analysis confirmed CXCR4 expression in tumors. Conclusion: Non-invasive imaging of CXCR4 expression using [68Ga]Pentixafor PET/CT of VS is feasible and could prove useful for in vivo assessment of CXCR4 expression.

KW - CXCR4

KW - Molecular imaging

KW - Pentixafor

KW - PET/CT

KW - Vestibular schwannoma

UR - http://www.scopus.com/inward/record.url?scp=85068976172&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85068976172&partnerID=8YFLogxK

U2 - 10.3389/fonc.2019.00503

DO - 10.3389/fonc.2019.00503

M3 - Article

C2 - 31245296

AN - SCOPUS:85068976172

VL - 9

JO - Frontiers in Oncology

JF - Frontiers in Oncology

SN - 2234-943X

IS - JUN

M1 - 503

ER -